INTRODUCTION

Agalsidase beta is a homodimeric glycoprotein produced using recombinant DNA technology. It is used in the treatment of Fabry disease.

This plasmid is designed for expression of agalsidase beta in Chinese hamster ovary (CHO) cells.

PRODUCT INFORMATION

Item No.: PPBD-5
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and antibiotic selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Agalsidase beta
Trade Name: Fabrazyme
Target: Human globotriaosylceramide
Action Type: Enzyme replacement
Amino Acid Sequence: Identical to DB00103

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Schaefer RM1, Tylki-Szymańska A, Hilz MJ. Drugs. 2009 Nov 12;69(16):2179-205. PMID: 19852524 DOI: 10.2165/11318300-000000000-00000

Contact Us